10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy). Safety and feasibility of imILT on LAPC will be evaluated as primary objective. Secondary objectives will be QoL after imILT, study of the immune reaction after imILT, oncological analysis of patients suffering from LAPC submitted to imILT.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
University of Verona Hospital
Verona, Italy
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: Up to 24 months
The immunostimulating effects of imILT
This will be determined by measuring plasma levels of various pro and anti-inflammatory cytokines and immune-related cells
Time frame: Up to 24 months
Overall Survival
Time frame: Up to 24 months
Progression free survival (PFS)
Time frame: Up to 24 months
Disease specific survival (DSS)
Time frame: Up to 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.